Sameer S. Kadri, MD, MS

MD, Seth G.S. Medical College
MS, Harvard School of Public Health

Dr. Kadri earned his degree in Medicine from the Seth G. S. Medical College and King Edward Memorial Hospital in Mumbai, India. He trained in Internal Medicine at the New York-Presbyterian/Weill Cornell Medical Center, Infectious Diseases at the Massachusetts General Hospital, in Critical Care at the NIH Clinical Center and in Clinical Epidemiology at the Harvard T.H. Chan School of Public Health.

Dr. Kadri was appointed to Staff Clinician in 2014 and more recently to Tenure Track Investigator in 2021 in the NIH Clinical Center’s Critical Care Medicine Department at the NIH Clinical Center. In this role, he splits his time between attending in the ICU, serving as an NIH principal investigator, supervising a data Lab, and training fellows.

His primary research interest lies in infections in the critically ill. He has leveraged large datasets for epidemiologic outcomes and comparative effectiveness investigations on antimicrobial resistance and sepsis, and more recently, COVID-19 to inform clinical care and health policy.

Since the Pandemic took hold in the U.S., Dr Kadri’s lab has contributed several landmark investigations to the evidence base, including studies showcasing the detrimental impact of strain of hospital COVID-19 caseload surges on outcomes, the reliability of diagnosis coding for COVID-19, the risk of reinfection from COVID-19 and the risk factors for severe outcome in vaccine breakthrough infections. He serves as a clinical advisor and collaborator on several CDC-initiated large database studies on COVID-19.

He founded and leads the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), a collaborative between the NIH Clinical Center, Intramural NIAID, the CDC and Harvard. He developed and tested a novel classification scheme for antimicrobial resistance called “Difficult-to-treat Resistance” or DTR that focuses on non-susceptibility to all first-line antibiotics. His group has performed studies comparing the real-world effectiveness of antibiotics used to treat infections for which clinical trials and unfeasible and unlikely. Hi lab collaborates closely with other federal agencies and several University-based investigators. Dr. Kadri has been awarded intramural and non-NIH grant funding and has won NIH CEO awards and other accolades from professional societies for his work.

Dr. Kadri has authored over 75 peer-reviewed publications and has served as a peer reviewer and held various editorial positions over the years. He has also spearheaded investigations that underscore the benefits of dually training in critical care medicine and infectious diseases. He is a fellow of the IDSA and serves on the society’s sepsis task force as well as on a CMS technical expert panel for developing an electronic performance measure for sepsis.

• 2021 NIH Clinical Center CEO Award for Science (for an impactful epidemiology lab)
• 2018 Society of Critical Care Medicine Star Research Gold Medal Award
• 2018 NIH Clinical Center CEO Award for Science (where RCTs are not possible)
• 2018 NIH Clinical Center CEO Award for Clinical Epidemiology Research

Journal Articles

Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, Silk BJ, Gundlapalli AV, Harris AM, Boehmer TK, Kadri SS. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):19-25. doi: 10.15585/mmwr.mm7101a4.

Kadri SS, Sun J, Lawandi A, Strich JR, Busch LM, Keller M, Babiker A, Yek C, Malik S, Krack J, Dekker JP, Spaulding AB, Ricotta E, Powers JH 3rd, Rhee C, Klompas M, Athale J, Boehmer TK, Gundlapalli AV, Bentley W, Datta SD, Danner RL, Demirkale CY, Warner S. Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. Ann Intern Med. 2021 Sep;174(9):1240-1251. doi: 10.7326/M21-1213.

Lawandi A, Warner S, Sun J, Demirkale CY, Danner RL, Klompas M, Gundlapalli A, Datta D, Harris AM, Morris SB, Natarajan P, Kadri SS. Suspected SARS-CoV-2 Reinfections: Incidence, Predictors, and Healthcare Use among Patients at 238 U.S. Healthcare Facilities, June 1, 2020- February 28, 2021. Clin Infect Dis. 2021 Aug 5:ciab671. doi: 10.1093/cid/ciab671.

Babiker A, Li X, Lai YL, Strich JR, Warner S, Sarzynski S, Dekker JP, Danner RL, Kadri SS. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. 2021 May;21(5):697-710. doi: 10.1016/S1473-3099(20)30523-5.

Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, Klompas M, Hooper DC, Powers JH 3rd, Srinivasan A, Danner RL, Adjemian J; forming the National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI). Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021 Feb;21(2):241-251. doi: 10.1016/S1473-3099(20)30477-1.

Kadri SS, Gundrum J, Warner S, Cao Z, Babiker A, Klompas M, Rosenthal N. Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations. JAMA. 2020 Dec 22;324(24):2553-2554. doi: 10.1001/jama.2020.20323.

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378.

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378.

Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. Published online: July 2018

Kadri SS. Recognizing the Unique Role of Critical Care Providers in Confronting Antimicrobial Resistance. Am J Respir Crit Care Med 2018 Jun 25.

Kadri SS, Swihart BJ, Bonne SL, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis with Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis 2017 Apr 1;64(7):877-885

Kadri SS, Rhee C, Strich JR Synergy, Salary, and Satisfaction: Benefits of Training in Critical Care Medicine and Infectious Diseases Gleaned from a National Pilot Survey of Dually Trained Physicians. Clin Infect Dis. 2016 Oct 1;63(7):868-875.

Kadri SS, Rhee C, Strich JR, et al. Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data. Chest 2017 Feb;151(2):278-285

Kadri SS, Miller AC, Hohmann S, et al. Risk factors for in-hospital mortality in smoke inhalation-associated acute lung injury: Data from 68 United States hospitals. Chest. 2016 Dec;150(6):1260-1268

Kadri SS, Rhee C, Fortna GS, O'Grady NP. Critical Care Medicine and Infectious Diseases: An Emerging Combined Subspecialty in the United States. Clin Infect Dis. 2015 Aug 15;61(4):609-14.

Kadri SS, Hohmann SF, Orav EJ, et al. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections. Clin Infect Dis. 2015 Jan 1;60(1):79-87

Chapters

Levine AR and Kadri SS. Infectious Diseases – Empiric and Emergency Treatment in Critical Care Handbook of the Massachusetts General Hospital, 6th Edition. Philadelphia, Lippincott, Williams & Wilkins, 2015.

Bonne SL, Kadri SS. – Evaluation and Management of Necrotizing Soft Tissue Infections in Complex Infectious Disease Issues in the Intensive Care Unit Infect Dis. Clinic North America Volume 31, Issue 3, 1^st Edition, Elsevier, 2017.

Visit PubMed.gov for a full list of Dr. Kadri's publications.